Compare BIO-TECHNE Corp (TECH) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard S&P 500 ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Vanguard S&P 500 ETF trades at $687.54. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals.
| TECH | VOO | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.12 | $698.29 |
52-Week Low | $43.31 | $571.45 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
VOO trades at $682.20, down 0.14% with a bearish technical signal from moving averages. The ETF shows neutral momentum indicators with RSI at 51.60, while support levels cluster around $677-681. Recent news highlights S&P 500 concentration risks and ongoing debates about market valuation levels amid tech dominance.
The outlook remains cautious as technical weakness contrasts with long-term ETF benefits. Key risks include market concentration in tech stocks and potential valuation concerns, while the dividend yield provides income support for patient investors seeking broad market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
